日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A CD8αβ co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands

经过修饰,含有胞内 CD28 信号尾的 CD8αβ 共受体可增强 TCR 工程化 T 细胞的功能,且该功能不依赖于实体瘤相关的共刺激配体。

Shihong Zhang #,Tzu-Hao Tang #,Sinéad Kinsella #,Francesco Mazziotta,Michael T Schweizer,Megan S McAfee,Ariunaa Munkhbat,Yapeng Su,Valentin Voillet,Lauren E Martin,Colton W Smith,Yuta Asano,Menna Hailemariam,Jakob Bakhtiari,Bo Lee,Cecilia Yeung,Hung Chen,Alessandro M Rizzi,Daniel G Chen,Kelsey Furiya,Nick Horst,Tianzi Zhang,Phung Le,Kelly McKenna,Shannon K Oda,Anthony Rongvaux,Phillip D Greenberg,Thomas M Schmitt,Aude G Chapuis

Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma models.

内源性 CD28 驱动 CAR T 细胞在骨髓瘤和淋巴瘤模型中的持续活性。

Lieberman Mackenzie M, Tong Jason H, Odukwe Nkechi U, Chavel Colin A, Bishara Gina G, Crasti Kimberly M, Herr Megan M, Goala Payal, Purdon Terence J, Burchett Rebecca, Gillard Bryan M, Brackett Craig M, Tario Joseph D, Rosario Spencer R, McGray Aj Robert, Bramson Jonathan L, Davila Marco L, Brentjens Renier J, Malek Ehsan, Lee Kelvin P, Olejniczak Scott H

Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain

学术型 CAR-T 细胞 ARI0002h 在整合跨膜 CD28 结构域后,对正常和低 BCMA 表达的骨髓瘤细胞表现出增强的抗肿瘤活性。

Cardus, Oriol; Mañé Pujol, Joan; de Daniel, Anna; Moreno, David F; Oliveira, Theo Gremen M; Battram, Anthony M; Salsench, Sergi V; Perez-Amill, Lorena; Llobregat, Helena; Carpio Mármol, Judit; Martin-Antonio, Beatriz; Oliver-Caldes, Aina; Munárriz, Daniel; Juan, Manel; Urbano-Ispizua, Alvaro; Rodríguez-Lobato, Luis Gerardo; Fernández de Larrea, Carlos

Correction: Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy

更正:靶向KK-LC-1的非超激动剂CD28双信号T细胞衔接器可增强抗肿瘤疗效

Non-superagonist CD28-based dual-signal T cell engager targeting.

基于非超激动剂 CD28 的双信号 T 细胞衔接器靶向治疗。

Chen Tianran, Wang Ying, Chen Xiaotong, Li Yuxiang, Guo Jingyi, Liu Fangcen, Shao Jie, Yan Jiayao, Li Mengzhu, Nie Jiaqi, Sun Qi, Liu Qin, Liu Baorui

PD-1 protects expanding human T cells from premature restimulation-induced cell death by modulating TCR and CD28 signaling.

PD-1 通过调节 TCR 和 CD28 信号传导来保护扩增的人类 T 细胞免受过早再刺激引起的细胞死亡。

Lee Katherine P, Elster Sara, Epstein Benjamin, Lake Camille M, Snow Andrew L

CD28-driven ex vivo generation of stem-like memory CD8(+) T cells bypassing CD3/TCR signaling

CD28驱动的体外干细胞样记忆CD8(+) T细胞生成绕过CD3/TCR信号传导

Ihara, Fumie; Ohashi, Yota; Zheng, Evey Y F; Fukao, Saori; Rodrigo, Rowena; Noamani, Babak; Boukhaled, Giselle M; Wang, Ben X; Han, Dong-Hoon; Wei, Xinyu; Burt, Brian D; Saso, Kayoko; Matsunaga, Yukiko; Ly, Dalam; Kagoya, Yuki; Butler, Marcus O; Mak, Tak W; Saibil, Samuel D; Hirano, Naoto

The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies

在B细胞恶性肿瘤的治疗中,基于4-1BB和CD28的CD19 CAR-T产品之间的竞争

Krawczyk, Marta; Drużyńska, Magdalena; Bednarska, Emilia; Winiarska, Magdalena

Overcoming the undruggable barrier: Structure-guided discovery of a potent small molecule CD28 antagonist with translational potential

克服“不可成药”障碍:基于结构的CD28小分子拮抗剂的发现及其转化潜力

Upadhyay, Saurabh; Nada, Hossam; Cho, Sungwoo; Gabr, Moustafa T

CD2 costimulation breaks the CD28 vs. 4-1BB tradeoff in CAR T cells

CD2共刺激打破了CAR-T细胞中CD28与4-1BB之间的权衡关系。

Posey, Avery D Jr